Relationship between increased levofloxacin use and decreased susceptibility of Streptococcus pneumoniae in the United States

被引:37
作者
Bhavnani, SM [1 ]
Hammel, JP
Jones, RN
Ambrose, PG
机构
[1] Ordway Res Inst, Inst Clin Pharmacodynam, Albany, NY 12208 USA
[2] SUNY Buffalo, Sch Pharm & Pharmaceut Sci, Buffalo, NY 14221 USA
[3] JMI Labs, JONES Grp, N Liberty, IA 52317 USA
[4] Tufts Univ, Sch Med, Boston, MA 02111 USA
[5] Cognigen Corp, Buffalo, NY 14221 USA
关键词
lexofloxacin; Streptococcus pneumoniae; fluoroquinolone resistance; United States;
D O I
10.1016/j.diagmicrobio.2004.08.017
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Increasing reports of fluoroquinolone-non-susceptible Streptococcus pneunioniae are of clinical concern. We examined the relationship between outpatient fluoroquinolone use and susceptibility of community -acquired S. pneumoniae isolates. Using multivariable general linear modeling, US SENTRY Antimicrobial Surveillance Program and Intercontinental Medical Statistics data (1997-2002) were analyzed to determine the influence of selected patient-, institution-, and geographic region-specific factors, including local fluoroquinolone usage, on the minimum inhibitory concentration (MIC) of levofloxacin against S. pneunioniae. Levofloxacin MIC50, MIC90, and MIC range (it = 3 84 from 26 hospitals) were 1, 1, and less than or equal to 0.5 to > 4 mug/mL, respectively. (.)Variables associated with changes in geometric mean MIC included geographical region (P < 0.0001), medical service (P = 0.0002), study year (P = 0.0006), primary diagnosis group (P = 0.02), and 2 interactions (duration of hospital stay before isolate collection by bed capacity, P = 0.06, and levofloxacin use by geographical region, P = 0.08; P < 0.001 when study year was removed from the model). MIC increased with levofloxacin use across all geographical regions, with increases of 54% and 126% in the southwest and west, respectively. In contrast to other fluoroquinolones, increased levofloxacin use, along with other variables, was associated with decreased pneumococcal susceptibility. Given the US environment of increasing pneumococcal resistance, these data may be useful in better understanding factors related to emergence of fluoroquinolone resistance. (C) 2005 Published by Elsevier Inc.
引用
收藏
页码:31 / 37
页数:7
相关论文
共 39 条
[1]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[2]   Emergence of levofloxacin-resistant pneumococci in immunocompromised adults after therapy for community-acquired pneumonia [J].
Anderson, KB ;
Tan, JS ;
File, TM ;
DiPersio, JR ;
Willey, BM ;
Low, DE .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (03) :376-381
[3]  
BEEKMANN SE, 2003, 43 INT C ANT AG CHEM, P140
[4]   Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in US hospitals [J].
Bhavnani, SM ;
Callen, WA ;
Forrest, A ;
Gilliland, KK ;
Collins, DA ;
Paladino, JA ;
Schentag, JJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2003, 60 (19) :1962-1970
[5]   Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of gram-negative pathogens [J].
Bhavnani, SM ;
Hammel, JP ;
Forrest, A ;
Jones, RN ;
Ambrose, PG .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (03) :344-350
[6]  
BHAVNANI SM, 2003, 41 INF DIS SOC AM SA, P33
[7]   Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995 [J].
Brueggemann, AB ;
Coffman, SL ;
Rhomberg, P ;
Huynh, H ;
Almer, L ;
Nilius, A ;
Flamm, R ;
Doern, GV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) :680-688
[8]  
*CDCP, 2001, MMWR-MORBID MORTAL W, V50, P800
[9]   Decreased susceptibility of Streptococcus pneumoniae to fluoroquinolones in Canada [J].
Chen, DK ;
McGeer, A ;
de Azavedo, JC ;
Low, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (04) :233-239
[10]  
CRAIG WA, 2000, 40 INT C ANT AG CHEM, P7